07/28/2021
Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to [email protected].
06/01/2021
Mycovia Pharmaceuticals, Inc. Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis
01/06/2021
Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from its Third Phase 3 Clinical Trial (ultraVIOLET) of Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis
12/09/2020
Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis
12/02/2020
